Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Aged
Benzhydryl Compounds
/ administration & dosage
Biomarkers
/ blood
Blood Glucose
/ drug effects
Canagliflozin
/ administration & dosage
Diabetes Mellitus, Type 2
/ blood
Drug Administration Schedule
Duration of Therapy
Female
Glucosides
/ administration & dosage
Glycated Hemoglobin
/ metabolism
Humans
Italy
Male
Middle Aged
Patient Safety
Retrospective Studies
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors
/ administration & dosage
Time Factors
Treatment Outcome
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
accepted:
14
10
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
28
4
2020
Statut:
epublish
Résumé
SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the long-term effectiveness and safety of SGLT-2 inhibitors in a Southern Italy population of subjects affected by T2DM. 408 diabetic patients treated with one of the three SGLT-2 inhibitors currently available in Italy (dapagliflozin, empagliflozin, and canagliflozin), either alone or in combination with other antidiabetic drugs, were retrospectively assessed at baseline, during, and after 18 months of continuous therapy. Treatment with SGLT-2 inhibitors resulted in a median decrease in HbA1c of 0.9%, with a percentage of decrement of 12 in relation to the baseline value, followed by a significant reduction ( In our patients' population, the glycometabolic effects of SGLT-2 inhibitors were durable and comparable to those observed in multicenter randomized controlled trials. This notwithstanding safety concerns must be raised regarding the frequent occurrence of genitourinary infections and the risk of a rapid decline of renal function in patients with evidence of volume depletion and/or receiving other medications which can adversely affect kidney function.
Sections du résumé
BACKGROUND
BACKGROUND
SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the long-term effectiveness and safety of SGLT-2 inhibitors in a Southern Italy population of subjects affected by T2DM.
PATIENTS AND METHODS
METHODS
408 diabetic patients treated with one of the three SGLT-2 inhibitors currently available in Italy (dapagliflozin, empagliflozin, and canagliflozin), either alone or in combination with other antidiabetic drugs, were retrospectively assessed at baseline, during, and after 18 months of continuous therapy.
RESULTS
RESULTS
Treatment with SGLT-2 inhibitors resulted in a median decrease in HbA1c of 0.9%, with a percentage of decrement of 12 in relation to the baseline value, followed by a significant reduction (
CONCLUSION
CONCLUSIONS
In our patients' population, the glycometabolic effects of SGLT-2 inhibitors were durable and comparable to those observed in multicenter randomized controlled trials. This notwithstanding safety concerns must be raised regarding the frequent occurrence of genitourinary infections and the risk of a rapid decline of renal function in patients with evidence of volume depletion and/or receiving other medications which can adversely affect kidney function.
Identifiants
pubmed: 31781664
doi: 10.1155/2019/3971060
pmc: PMC6875368
doi:
Substances chimiques
Benzhydryl Compounds
0
Biomarkers
0
Blood Glucose
0
Glucosides
0
Glycated Hemoglobin A
0
Sodium-Glucose Transporter 2 Inhibitors
0
hemoglobin A1c protein, human
0
Canagliflozin
0SAC974Z85
dapagliflozin
1ULL0QJ8UC
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3971060Informations de copyright
Copyright © 2019 Maria Mirabelli et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Diabetes Care. 2017 Apr;40(4):e40-e41
pubmed: 28130255
Am J Cardiol. 2018 Sep 15;122(6):981-984
pubmed: 30075890
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103
pubmed: 25470017
Diabetes Metab J. 2019 Oct;43(5):590-606
pubmed: 30877709
Drugs. 2015 Jan;75(1):33-59
pubmed: 25488697
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Diabetes Care. 2000 Apr;23 Suppl 2:B21-9
pubmed: 10860187
Expert Rev Endocrinol Metab. 2017 May;12(3):155-158
pubmed: 30063457
Diabetes Technol Ther. 2015 Jul;17(7):468-74
pubmed: 25844858
Sci Rep. 2013;3:1491
pubmed: 23512162
Diabetes Obes Metab. 2017 Mar;19(3):348-355
pubmed: 27862830
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Expert Opin Drug Saf. 2016 Oct;15(10):1401-12
pubmed: 27449721
Postgrad Med. 2016 May;128(4):346-55
pubmed: 26878357
Diabetes Obes Metab. 2014 Nov;16(11):1111-20
pubmed: 24919526
J Am Heart Assoc. 2017 May 25;6(6):null
pubmed: 28546454
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Circulation. 2001 Oct 16;104(16):1985-91
pubmed: 11602506
Arch Intern Med. 2011 Mar 14;171(5):412-20
pubmed: 21403038
J Diabetes Investig. 2019 Mar;10(2):439-445
pubmed: 30136398
Curr Hypertens Rep. 2014 Aug;16(8):461
pubmed: 24903233
World J Diabetes. 2014 Apr 15;5(2):128-40
pubmed: 24748926
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Lancet. 1998 Sep 12;352(9131):854-65
pubmed: 9742977
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Diabetes Care. 2018 Aug;41(8):1543-1556
pubmed: 30030256
Postgrad Med. 2011 Jul;123(4):38-45
pubmed: 21680987
N Engl J Med. 2017 Aug 31;377(9):839-848
pubmed: 28854085
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Diabetes Obes Metab. 2019 Feb;21(2):340-348
pubmed: 30207040
Endocr Pract. 2018 Mar;24(3):273-287
pubmed: 29547044
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
N Engl J Med. 2016 Nov 3;375(18):1798-9
pubmed: 27806225
Curr Med Res Opin. 2014 Jun;30(6):1109-19
pubmed: 24517339
J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9
pubmed: 24602971
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71
pubmed: 27440829
Diabetologia. 2007 Mar;50(3):549-54
pubmed: 17187246
J Med Microbiol. 1999 Jun;48(6):535-9
pubmed: 10359302
Diabetol Metab Syndr. 2017 Dec 1;9:96
pubmed: 29213337
Adv Ther. 2019 Jan;36(1):44-58
pubmed: 30465123
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85
pubmed: 29222379
Diabetes Obes Metab. 2014 May;16(5):457-66
pubmed: 24320621
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227